PARP14 inhibitor treatment would not be efficacious as a monotherapy, as PARP14 antagonism or knockdown did not affect the ex vivo growth of the tumour cell lines we evaluated, nor did monotherapy significantly alter their tumour growth potential, even following chronic IFNγ stimulation. The gene discussed is PARP14; the disease is neoplasm.